NASDAQ:MESO Mesoblast (MESO) Stock Price, News & Analysis $7.40 -0.02 (-0.27%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.30▼$7.5950-Day Range$6.45▼$8.5252-Week Range$1.61▼$8.66Volume89,193 shsAverage Volume1.10 million shsMarket Capitalization$844.93 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Mesoblast alerts: Email Address Mesoblast MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside116.2% Upside$16.00 Price TargetShort InterestHealthy0.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.71) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector532nd out of 936 stocksBiological Products, Except Diagnostic Industry81st out of 154 stocks 3.2 Analyst's Opinion Consensus RatingMesoblast has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMesoblast has only been the subject of 2 research reports in the past 90 days.Read more about Mesoblast's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.33% of the outstanding shares of Mesoblast have been sold short.Short Interest Ratio / Days to CoverMesoblast has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mesoblast has recently decreased by 18.94%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MESO. Previous Next 2.4 News and Social Media Coverage News SentimentMesoblast has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Mesoblast this week, compared to 3 articles on an average week.Search Interest9 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Mesoblast to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock.Percentage Held by Insiders18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 1.43% of the stock of Mesoblast is held by institutions.Read more about Mesoblast's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mesoblast are expected to grow in the coming year, from ($0.71) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMesoblast has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Mesoblast's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Mesoblast Stock (NASDAQ:MESO)Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Read More MESO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MESO Stock News HeadlinesJuly 26 at 7:10 AM | americanbankingnews.comMesoblast (NASDAQ:MESO) Upgraded to Overweight at Piper SandlerJuly 23, 2024 | marketwatch.comMesoblast's Gets FDA Acceptance of Application for Allogeneic Cellular TherapyJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 23, 2024 | finance.yahoo.comFDA accepts Mesoblast’s latest BLA for paediatric GvHD cell therapyJuly 23, 2024 | globenewswire.comFDA Accepts Mesoblast's Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)July 23, 2024 | marketwatch.comMesoblast Shares Rise on Start of Late-Stage Trial For Low Back Pain TreatmentJuly 22, 2024 | finanznachrichten.deMesoblast Limited: Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainJuly 22, 2024 | msn.comUp 308% in 6 months, why is the Mesoblast share price tumbling today?July 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | finance.yahoo.comMesoblast begins subject enrolment in Phase III back pain treatment trialJuly 21, 2024 | globenewswire.comPatient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back PainJuly 21, 2024 | americanbankingnews.comMesoblast (NASDAQ:MESO) Shares Gap Up to $7.10July 21, 2024 | americanbankingnews.comMesoblast Limited (NASDAQ:MESO) Receives Average Rating of "Hold" from BrokeragesJuly 8, 2024 | globenewswire.comMesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)July 1, 2024 | globenewswire.comMesoblast to File Biologics License Application for Ryoncil® FDA Approval Next WeekJune 2, 2024 | globenewswire.comMesoblast Corporate Presentation at Investor ConferenceMay 28, 2024 | msn.comASX 200 ‘drifts off’ after ‘weaker-than-expected’ retail sales numbersMay 27, 2024 | msn.comOvercoming long-term unemployment by getting physically and mentally fit to join the workforceSee More Headlines Receive MESO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mesoblast and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/30/2023Today7/26/2024Next Earnings (Estimated)9/04/2024Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIK1345099 Webwww.mesoblast.com Phone(139) 639-6036Fax61-3-9639-6030Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$16.00 High Stock Price Target$34.00 Low Stock Price Target$3.00 Potential Upside/Downside+116.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.21 Current Ratio2.71 Quick RatioN/A Sales & Book Value Annual Sales$7.50 million Price / Sales112.66 Cash FlowN/A Price / Cash FlowN/A Book Value$6.16 per share Price / Book1.20Miscellaneous Outstanding Shares114,180,000Free Float92,713,000Market Cap$844.93 million OptionableOptionable Beta3.48 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Silviu Itescu FACP (Age 67)FACRA, FRACP, MBBS (Hons), Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Comp: $738.74kDr. Eric A. Rose M.D. (Age 73)Chief Medical Officer & Executive Director Comp: $625.46kMr. Andrew Chaponnel B.Com.Interim Chief Finance OfficerMr. Peter T. Howard B.Sc. (Age 56)L.L.B., LLB (Hons), General Counsel & Corporate Executive Mr. Roger D. Brown BAHead of Spinal Orthopedic DisordersMr. Michael Schuster BSc (Age 47)M.B.A., MS, Head of Pharma Partnering Ms. Geraldine Storton B.Sc.M.B.A., MMS, Head of Regulatory Affairs & Quality ManagementMr. Justin Horst B.S.Head of ManufacturingMs. Niva Sivakumar B.Com.L.L.B., Joint Company SecretaryMr. Paul Hughes BPHARMJoint Company SecretaryMore ExecutivesKey CompetitorsArcellxNASDAQ:ACLXXenon PharmaceuticalsNASDAQ:XENEMerusNASDAQ:MRUSADMA BiologicsNASDAQ:ADMARhythm PharmaceuticalsNASDAQ:RYTMView All CompetitorsInstitutional OwnershipChapin Davis Inc.Bought 5,000 shares on 7/19/2024Ownership: 0.013%Perkins Coie Trust CoBought 10,000 shares on 7/15/2024Ownership: 0.009%GAMMA Investing LLCBought 1,663 shares on 7/2/2024Ownership: 0.004%Lazari Capital Management Inc.Sold 45,267 shares on 6/24/2024Ownership: 0.044%Chase Investment Counsel CorpBought 59,600 shares on 5/2/2024Ownership: 0.052%View All Institutional Transactions MESO Stock Analysis - Frequently Asked Questions How have MESO shares performed this year? Mesoblast's stock was trading at $2.20 at the beginning of 2024. Since then, MESO shares have increased by 236.4% and is now trading at $7.40. View the best growth stocks for 2024 here. How were Mesoblast's earnings last quarter? Mesoblast Limited (NASDAQ:MESO) announced its earnings results on Wednesday, August, 30th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.06. The company had revenue of $2.14 million for the quarter, compared to analyst estimates of $2 million. When did Mesoblast's stock split? Mesoblast's stock reverse split on the morning of Friday, January 5th 2024. The 1-2 reverse split was announced on Friday, January 5th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 50 shares after the split. When did Mesoblast IPO? Mesoblast (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's top institutional shareholders include Chapin Davis Inc. (0.01%), Perkins Coie Trust Co (0.01%) and GAMMA Investing LLC. How do I buy shares of Mesoblast? Shares of MESO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mesoblast investors own include Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Exelixis (EXEL), CRISPR Therapeutics (CRSP) and Novavax (NVAX). This page (NASDAQ:MESO) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
